Junichiro Nakata

Dr. Junichiro Nakata


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
MKMasako Kuwasawa-Iwasaki
Masako Kuwasawa-Iwasaki
HIHiroaki Io
Hiroaki Io
MMMasahiro Muto
Masahiro Muto
SISaki Ichikawa
Saki Ichikawa
KWKeiichi Wakabayashi
Keiichi Wakabayashi
YSYusuke Suzuki
Yusuke Suzuki
L-carnitine is an important factor in fatty acid metabolism, and carnitine deficiency is common in dialysis patients. This study evaluated whether l-carnitine supplementation improved muscle spasm, cardiac function, and renal anemia in dialysis patients. Eighty Japanese outpatients (62 hemodialysis (HD) patients and 18 peritoneal dialysis (PD) patients) received oral l-carnitine (600 mg/day) for 12 months; the HD patients further received intravenous l-carnitine injections (1000 mg three times/week) for 12 months, amounting to 24 months of treatment. Muscle spasm incidence was assessed using a questionnaire, and cardiac function was assessed using echocardiography. Baseline free carnitine concentrations were relatively low in patients who underwent dialysis for >4 years. Total carnitine serum concentration, free carnitine, and acylcarnitine significantly increased after oral l-carnitine treatment for 12 months, and after intravenous l-carnitine injection. There was no significant improvement in muscle spasms, although decreased muscle cramping after l-carnitine treatment was reported by 31% of patients who had undergone HD for >4 years. Hemoglobin concentrations increased significantly at 12 and 24 months in the HD group. Therefore, l-carnitine may be effective for reducing muscle cramping and improving hemoglobin levels in dialysis patients, especially those who have been undergoing dialysis for >4 years.

30 October 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HIHiroaki Io
Hiroaki Io
JNJunichiro Nakata
Junichiro Nakata
HIHiroyuki Inoshita
Hiroyuki Inoshita
MIMasanori Ishizaka
Masanori Ishizaka
YTYasuhiko Tomino
Yasuhiko Tomino
YSYusuke Suzuki
Yusuke Suzuki
This study aimed to identify the ideal timing and setting for measuring blood pressure (BP) and determine whether the left ventricular mass index (LVMI) is an independent risk factor associated with increased cardiovascular events in hemodialysis (HD) patients. BP and LVMI were measured at baseline and at 6 and 12 months after HD initiation. BP was monitored and recorded at nine different time points, including before and after HD over a one-week period (HDBP). The mean BP measurement was calculated as the weekly averaged BP (WABP). LVMI was significantly correlated with home BP, in-office BP, HDBP, and WABP. Receiver operating characteristic analysis indicated that the cutoff LVMI value for cardiovascular events was 156 g/m2. LVMI and diabetes mellitus were significant influencing factors for cardiovascular events (hazards ratio (95% confidence interval): diabetes mellitus, 2.84 (1.17,7.45); LVMI > 156 g/m2, 2.86 (1.22,6.99)). Pre-HDBP, post-HDBP, and WABP were independently associated with higher LVMI in the follow-up periods. Hemoglobin and human atrial natriuretic peptide (hANP) levels were associated with LVMI beyond 12 months after HD initiation. Treatment of hypertension, overhydration based on hANP, and anemia may reduce the progression of LVMI and help identify HD patients at high risk for cardiovascular events.

14 April 2016 in SpringerPlus
Verified
Journal Article
Open access
PDF file
JNJunichiro Nakata
Junichiro Nakata
HIHiroaki Io
Hiroaki Io
TWTomonari Watanabe
Tomonari Watanabe
YSYu Sasaki
Yu Sasaki
YMYuko Makita
Yuko Makita
YTYasuhiko Tomino
Yasuhiko Tomino
Although ultrasonography before a vascular access (VA) operation has become popular in recent years, benchmarks for the diameter or blood flow of arteries or veins are not defined in Japan. The objective of the present study is to analyze the relationship between preoperative US findings and the patency rate of VA in Japanese hemodialysis patients. 139 patients with end stage kidney disease were enrolled in this study. They had been given primary radiocephalic arteriovenous fistula (AVF) from February 2009 to December 2010 at the Juntendo University Hospital and were followed up over 2 years. We defined the interval from the time of AVF creation until first access thrombosis or any intervention to maintain or restore blood flow as patency time (primary patency). We examined the correlation between the 2-year primary patency rate of VA and the diameter of the radial artery (RA), brachial artery (BA), or cephalic vein at an anastomosis presumptive region by US, the blood flow of RA or BA, as measured by US, age, gender, and primary kidney diseases. The average patency term was 448.6 ± 271.3 days, with the 1-year and 2-year patency rate as 64.0 and 51.2 %, respectively. The patency rate was significantly lower in elderly patients over the age of 75 and in patients with diabetes mellitus. US findings of 2.0 mm or less in the RA diameter also resulted in a noticeably low patency rate. A multivariate analysis indicated that those factors were risk factors for early VA failure. Preoperative US findings of the diameter of RA may involve the patency rate of VA, making it appears that an RA of 2.0 mm or more in diameter at an anastomosis region may be more effective for the improvement in the patency rate of VA.

14 April 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
Yuji UenoYuji Ueno
Yuji Ueno
ASAsami Saito
Asami Saito
JNJunichiro Nakata
Junichiro Nakata
KKKoji Kamagata
Koji Kamagata
DTDaisuke Taniguchi
Daisuke Taniguchi
NHNobutaka Hattori
Nobutaka Hattori
Although l-carnitine alleviated white-matter lesions in an experimental study, the treatment effects of l-carnitine on white-matter microstructural damage and cognitive decline in hemodialysis patients are unknown. Using novel diffusion magnetic resonance imaging (dMRI) techniques, white-matter microstructural changes together with cognitive decline in hemodialysis patients and the effects of l-carnitine on such disorders were investigated. Fourteen hemodialysis patients underwent dMRI and laboratory and neuropsychological tests, which were compared across seven patients each in two groups according to duration of l-carnitine treatment: (1) no or short-term l-carnitine treatment (NSTLC), and (2) long-term l-carnitine treatment (LTLC). Ten age- and sex-matched controls were enrolled. Compared to controls, microstructural disorders of white matter were widely detected on dMRI of patients. An autopsy study of one patient in the NSTLC group showed rarefaction of myelinated fibers in white matter. With LTLC, microstructural damage on dMRI was alleviated along with lower levels of high-sensitivity C-reactive protein and substantial increases in carnitine levels. The LTLC group showed better achievement on trail making test A, which was correlated with amelioration of disorders in some white-matter tracts. Novel dMRI tractography detected abnormalities of white-matter tracts after hemodialysis. Long-term treatment with l-carnitine might alleviate white-matter microstructural damage and cognitive impairment in hemodialysis patients.

18 December 2024 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NUNaoto Usui
Naoto Usui
JNJunichiro Nakata
Junichiro Nakata
AUAkimi Uehata
Akimi Uehata
SKSho Kojima
Sho Kojima
SAShuji Ando
Shuji Ando
YSYusuke Suzuki
Yusuke Suzuki
Key Points: This study analyzed the prognostic value of reserves obtained from cardiopulmonary exercise testing in patients on hemodialysis. Each reserve (cardiac, autonomic, and muscular) was associated with mortality, with muscle reserve having the highest prognostic accuracy. Patients with physical frailty also had a fairly good prognosis if their physiological reserve is preserved by exercise testing. Background: Potential impairment of exercise capacity is prevalent even in patients undergoing hemodialysis without frailty. Cardiopulmonary exercise testing (CPET) can detect physiological reserves, such as cardiopulmonary, muscle, and autonomic function. We hypothesized that these indices could accurately determine the prognosis of patients on hemodialysis and analyzed them on the basis of their relationship to frailty. Methods: In this two-center prospective cohort study of patients on hemodialysis from Japan, patients underwent CPET and physical assessment to evaluate peak oxygen uptake (peak VO2, indicator of exercise capacity), peak work rate (WR, indicator of muscle function), ventilatory equivalent for carbon dioxide (VE/VCO2) slope (indicator of cardiac reserve), heart rate reserve (indicator of chronotropic incompetence), and frailty phenotype. Survival was followed up for up to 5 years. Results: Data from 189 patients (median [interquartile range] age: 71 [62–77] years) were analyzed. All CPET indicators showed a consistent nonlinear relationship with all-cause mortality after adjustment: for peak VO2, hazard ratio (HR), 0.79 (95% confidence interval [CI], 0.71 to 0.88), P < 0.001; for peak WR, HR, 0.95 (95% CI, 0.93 to 0.97), P < 0.001; for VE/VCO2 slope, HR, 1.09 (95% CI, 1.05 to 1.13), P < 0.001; and for heart rate reserve, HR, 0.96 (95% CI, 0.93 to 0.99), P = 0.02. Frailty phenotype was associated with mortality after adjustment (HR, 1.73 [95% CI, 1.06 to 2.81], P = 0.03); however, this association was not statistically significant in the model after adding peak VO2 (P = 0.41). Furthermore, in both subgroups with and without frailty, CPET measures were significantly associated with mortality risk (peak VO2, peak WR, and VE/VCO2 slope: P < 0.05). The peak VO2 (Δ area under the curve, 0.09; 95% CI, 0.02 to 0.16) or the peak WR (Δ area under the curve, 0.09; 95% CI, 0.02 to 0.15) most significantly improved the prognostic accuracy. Conclusions: Results showed the fragile aspect of the frailty phenotype in the hemodialysis population and the superior ability of CPET to indicate death risk complementing that aspect.

13 October 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
TKToshiki Kano
Toshiki Kano
HIHiroaki Io
Hiroaki Io
JNJunichiro Nakata
Junichiro Nakata
YSYu Sasaki
Yu Sasaki
MMMasahiro Muto
Masahiro Muto
YSYusuke Suzuki
Yusuke Suzuki
Background: Arterial calcification is an important factor in determining the prognosis of patients with chronic kidney disease (CKD). Few studies on aortic calcification have involved radial artery calcification (RAC). This study aimed to analyze risk factors for RAC in patients with end-stage kidney disease (ESKD) and investigate the relationship between subsequent cardiovascular events (CVE) and vascular access trouble (VAT). Methods: This cohort study included 64 consecutive patients with ESKD who initiated hemodialysis and underwent a procedure for the creation of a primary radiocephalic arteriovenous fistula (RCAVF). Small arterial specimens were obtained from patients during RCAVF surgery. Tissue samples were stained with von Kossa, and arterial microcalcification was evaluated. We analyzed the association between preexisting arterial microcalcifications, clinical characteristics, CVE, and VAT. Results: In the univariate analysis, RAC patients demonstrated high systolic blood pressure (sBP), low hemoglobin (Hb), and low transferrin saturation (TSAT) (<0.05, <0.05, and <0.05, respectively). In the multivariate analysis, Hb (HR–0.516 (0.278–0.959), p < 0.05), TSAT (HR–0.0012 (0.00000248–0.597), p < 0.05), and sBP (HR–1.037 (1.001–1.073), p < 0.05) were independent risk factors for RAC. The cumulative incidence rate of CVE/VAT was not associated with RAC for one year. Conclusion: RAC was associated with sBP, TSAT, and anemia; however, no association with CVE/VAT was observed.